Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Earnings Results

Recursion Pharmaceuticals (NASDAQ:RXRX) issued its quarterly earnings results on Friday. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17), Zacks reports. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $4.60 million for the quarter, compared to analysts’ expectations of $19.04 million. During the same quarter in the previous year, the business earned ($0.42) EPS. The company’s revenue for the quarter was down 57.8% on a year-over-year basis.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX traded down $0.34 during trading hours on Friday, hitting $7.34. The stock had a trading volume of 29,348,188 shares, compared to its average volume of 25,924,594. The company has a 50 day simple moving average of $7.69 and a two-hundred day simple moving average of $7.07. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of -4.78 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a one year low of $5.60 and a one year high of $14.12.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RXRX shares. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.